Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease

Archives of Internal Medicine

Volumn 156, Issue 8, 1996, Pages 889-894

  Graham, Neil M H ^a,b   Galai, Noya ^a   Nelson, Kenrad E ^a,b   Astemborski, Jacqueline ^a   Bonds, Margaret ^a   Rizzo, Rosetta T ^c   Sheeley, Laura ^a   Vlahov, David ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Baltimore Food Policy Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULIN;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; ISONIAZID; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS;

EID: 0029872822     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.8.889     Document Type: Article

References (38)

1. Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivrty and skin test anergy in HIV-1 seropositive and seronegative drug users. JAMA. 1992;267-369-372.
2. Robert CF, Hirschel B, Rochat T, Deglon JJ. Tuberculin skin test reactivity in HIV seropositive intravenous drug addicts. N Engl J Med. 1989,321:1268.
3. Markowitz N, Hansen NI, Wilcosley TL, et al. Tuberculin and anergy testing in HIV seropositive and HIV seronegative persons. Ann Intern Med 1993,119 185-193.
4. Reichman LB, Felton CP, Edsall JR Drug dependence. a possible new risk factor for tuberculosis disease. Arch Intern Med. 1979,139.337-339.
5. Centers for Disease Control and Prevention Expanded tuberculosis surveillance and tuberculosis morbidity - United States, 1993 MMWR Morb Mortal Wkly Rep. 1994;43:361-366.
6. Galai N, Graham NMH, Chaisson R, Nelson K, Vlahov D, Lewis J Multi-drug resistant tuberculosis N Engl J Med. 1992,3272:172-1173.
7. Slutsker L, Castro KG, Ward JW, Dooley SW. Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. Clin Infect Dis. 1993;16:513-518.
8. Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York City. Science. 1988;242.916-919.
9. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study ot the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320.545-550.
10. Selwyn PA, Sckeil BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV infected drug users with cutaneous anergy. JAMA 1992,268:504-509.
11. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV Ann Intern Med 1993;119:194-198.
12. Girardi E, Antonucci G, Ippolito G, et al. Prospective evaluation of risk of tuberculosis in HIV infected persons by tuberculin reaction size. In: Program and abstracts of the Tenth International Conference on AIDS; August 1994; Tokyo, Japan.
13. Birx D, Rhoads J, Tramont E, et al Correlation of in vitro cellular immunity with CD4 number and disease progression in HIV seropositive patients. In: Program and abstracts of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal. Quebec.
14. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed type hypersentivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med. 1993; 119:177-184
15. Daley CL, Small PM, Schecter GF, et al An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med 1992;326:231-235
16. Jordon TJ, Lewit EM, Montgomery RL, Reichman LB. Isomazid as preventive therapy in HIV-infected intravenous drug abusers: a decision analysis. JAMA 1991;265:2987-2991.
17. Graham NMH, Chaisson RE. Tuberculosis and HIV infection: epidemiology, pathogenesis, and clinical aspects Ann Allergy. 1993;71:421-428.
18. Caiaffa WT, Graham NMH, Astemborski J, Rizzo RT, Nelson KE, Vlahov D Instability of delayed-type hypersensitivity (DTH) skin test anergy in human immunodeficiency virus infection. Arch Intern Med. 1995;155:2111-2117
19. Pape JW, Jean SS, Hafner A, Johnson WD, Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272.
20. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: 5 years' follow-up in the IUAT trial Bull World Health Organ 1982;60:555-564.
21. Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET) MMWR Morb Mortal Wkly Rep 1989;38:236-238
22. Centers for Disease Control. The use of preventive therapy for tuberculosis infection in the United States recommendations of the Advisory Committee for the Elimination of Tuberculosis MMWR Morb Mortal Wkly Rep. 1990;39:9-12.
23. Vlahov D, Anthony JC, Muñoz A, et al. The ALIVE Study, a longitudinal study of HIV-1 infection among intravenous drug users: description of methods and characteristics of participants. J Drug Issues. 1991;21:755-771.
24. Giorgi J, Cheng HL, Margolick J, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study (MACS) experience Clin Immunol Immunopathol. 1990,55:173-186
25. Chaulk CP, Moore-Rice K, Rizzo RT, Chaisson RE. Fifteen years of directly observed therapy for tuberculosis: a tale of six cities. JAMA. 1995;274:945-951.
26. Comstock GW Variability of tuberculosis trends in a time of resurgence. Clin Infect Dis. 1994;19:1015-1022.
27. Rieder HL, Cauthen GM, Comstock GW, Snider DE. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11.79-98.
28. Hinman AR Disease prevention programs for racial and ethnic minorities. Ann Epidemiol. 1993;3:185-192.
29. Drucker E, Alcabes P, Bosworth W, Sckell B Childhood tuberculosis in the Bronx, New York. Lancet. 1994;343:1482-1485.
30. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. human immunodeficiency virus, homelessness, and the decline of tuberculosis programs. Am J Respir Grit Care Med 1991;144.745-749.
31. Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324.1332-1338.
32. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zieovudine. Am J Respir Crit Care Med 1992;146.285-289.
33. Horsburgh CR, Chin DP, Yajko DM, et al. Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus. J Infect Dis. 1994;170:362-367.
34. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium aviumintracellulare complex bacteremia in human immunodeficiency virus positive patients. J Infect Dis. 1992;165:1082-1085.
35. Hoover DR, Graham NMH, Bacellar M, et al An epidemiologic analysis of Mycobacterium avium complex disase in HIV-1 infected homosexual men. Clin Infect Dis. 1995,20:1250-1258
36. Shafer RW, Sierra MF Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other non-tuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis. 1992;15 161-162
37. Razka WV, Skillman LP, McEvoy PL, Robb LM Isolation of non-tuberculous non-avium mycobacteria from patients infected with human immunodeficiency virus Clin Infect Dis. 1995,20 73-76.
38. Hoover DR, Saah AJ, Bacellar M, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993,329:2222-2226.